Innova Captab: June-quarter profit up 42%, but the FY26 accounts were revised in August and at ₹1,110 the stock trades at 41x profit
Innova Captab made ₹44 crore of profit in the June quarter, 42% more than a year earlier, on sales of ₹471 crore, up 34%. In August it also revised its audited FY26 accounts and restated FY25. The stock closed at ₹1,110 on 9 October, about 41 times its last twelve months of profit. That price needs the new Jammu plant to fill up, and it is only 25% to 30% full.
Innova Captab (NSE: INNOVACAP, BSE: 544067) - Share price: ₹1,110.00 (NSE close of 9 October 2026; markets were shut on 10 October) - Market cap: ₹6,352 crore - P/E: 41.2 on the data site's last twelve months of profit. On profit after the August revision (about ₹157 crore) it is about 40. Peers: Akums Drugs 38.8, Windlas Biotech 29.5, Syngene 47.4, Concord Biotech 51.3 - Book value: ₹191 per share, so the stock trades at about 5.8 times book value - 52-week range: about ₹608 to ₹1,354 (data sites differ slightly on the low). The price is about 83% above the low and 18% below the high - Listed on the NSE and BSE main boards in December 2023, so it is not an SME stock
What Innova Captab does
Innova Captab was incorporated in January 2005. Its first plant opened in Baddi, Himachal Pradesh, in 2006. It makes tablets, capsules, syrups, ointments, powders for injection and, at its newest plant, injectable and respiratory products. It runs two businesses that share the same factories.
- Contract manufacturing (CDMO): about 70% of sales (₹1,133 crore in FY26, up 24%). Other drug companies pay Innova to make their medicines. It has more than 350 such customers. Management describes the model as cost plus a margin, with raw material price changes generally passed on to customers (timing gaps can still move the margin) - Branded generics: about 30% of sales (₹497 crore in FY26, up 51%). Innova sells medicines under its own brands to doctors and chemists, in India and abroad. Its subsidiary Sharon Bio-Medicine, bought on 30 June 2023, makes up about ₹240 crore of this and sells in regulated markets such as the UK, Canada and Europe. Sharon's margin is better than the group average
About 70% of sales are in India and 30% are exports (31% in FY26 and 32% in the June quarter). The company lists 4,200 products and sales in more than 60 countries. The filings I read do not name any customer or say how much one customer contributes, so I cannot judge customer concentration.
Four plant groups make the products:
- Baddi, Himachal Pradesh: the original multi-product site, including a cephalosporin (a type of antibiotic) block that received a UK-MHRA quality certificate - Dehradun and Taloja: the Sharon plants, which management says are close to full use - Kathua, Jammu: a ₹480+ crore plant with four separate blocks, started in January 2025. It makes penem, beta-lactam and cephalosporin antibiotics, general injectables and respules. It received a PIC/S quality certificate through the Ukrainian regulator SMDC
The Jammu plant gets government incentives: a GST-linked benefit of up to 300% of the investment in eligible plant and machinery for 10 years, and a 6% a year interest subsidy on loans for eligible capex. This comes from the company's investor presentation.
Who runs it
Promoters hold 50.90%, unchanged since listing.
Person Role ------ Manoj Kumar Lohariwala Chairman and whole-time director Vinay Lohariwala Managing director Jayant Vasudeo Rao Whole-time director Archit Aggarwal Non-executive director Lokesh Bhasin Chief financial officer
The board has four independent directors: Sudhir Kumar Bassi, Priyanka Dixit Sibal, Mahendar Korthiwada and Shirish Gundopant Belapure. The auditor is BSR & Co. LLP.
The filings I read do not give ages, qualifications or earlier jobs for the promoters and executives, so I am not stating them. I found no regulatory action or court case against the company or its promoters in the filings I read. I did not review the related-party table in the annual report. On the August call, management said the branded generics business is treated as an ordinary customer of its own plants, with products transferred at arm's length prices.
The numbers: steady growth, margins near 15%
₹ crore (consolidated) FY22 FY23 FY24 FY25 FY26 ------------------ Sales 801 926 1,081 1,244 1,630 Operating profit (EBITDA, company's count) 99 123 167 198 250 EBITDA margin 12.4% 13.3% 15.4% 15.9% 15.4% Profit after tax (PAT) 64 68 94 127 143 Earnings per share (₹) n/a 14.16 16.49 22.24 25.02
Revised in August 2026 (see below). FY22 to FY24 are as originally reported.
Sales doubled in four years and profit rose 2.2 times. The last twelve months to June 2026 show sales of ₹1,749 crore and operating profit of ₹259 crore, a margin of about 15%.
The June 2026 quarter: - Sales ₹470.9 crore, up 34%. CDMO ₹328.7 crore (up 32%) and branded generics ₹142.2 crore (up 39%) - EBITDA ₹75.1 crore, up 33%, a margin of 16.0%. A year earlier it was 16.1% - Profit after tax ₹44.1 crore, up 42% - Volume grew 20% to 22%. The rest of the growth came from a richer product mix and better prices. Without Jammu, volume grew 12% to 14% - Gross margin was about 35.5%, down 1% to 1.5% on a year ago because of the mix
₹ crore Jun-25 Sep-25 Dec-25 Mar-26 Jun-26 ------------------ Sales 352 380 450 448 471 Operating profit 52 52 69 65 73 Operating margin 15% 14% 15% 15% 16% Profit after tax 31 30 42 40 44
Revised figure. Operating profit in this table excludes other income. The company's EBITDA includes it, which is why June 2026 shows ₹73 crore here and ₹75.1 crore in the company's figures.
The quarterly operating margin has stayed between 13% and 16% for about three years. According to management, the Jammu plant is the main reason it is not higher. It earned only ₹1 crore to ₹1.5 crore of operating profit on ₹107 crore of sales in the June quarter, its first profitable quarter. Without Jammu, the margin was about 20%. FY26 profit rose only 12.5% (on the revised numbers) against 31% sales growth, because Jammu's depreciation and interest are fixed costs that began before it had enough sales.
The September 2026 quarter is over but its results are not out. They are due by 14 November.
The August revision of the accounts
This is the most important event in the filings. On 7 May 2026 the board approved audited FY26 results. On 22 August, after the board met late on 21 August, the company approved revised audited results for FY26, with a fresh unmodified audit report from BSR & Co. The filing calls the changes "inadvertent errors". These are the changes:
- Prior-year restatement (consolidated). A deferred tax liability (a tax bill that falls due in the future) linked to the Sharon acquisition on 30 June 2023 had never been recorded. As a result, net worth, which is the value left for shareholders after liabilities, was shown higher than it should have been. The company corrected it for earlier periods. Net worth at 1 April 2024 fell by ₹105 crore, to ₹820 crore. At 31 March 2025 it fell by ₹115 crore, to ₹948 crore. (The FY26 net worth change of minus ₹9 crore is at a different date and has other causes, so the figures are not additive.) FY25 profit was restated from ₹128.3 crore to ₹127.3 crore, and FY25 earnings per share from ₹22.41 to ₹22.24. The filing shows no cash impact - FY26 profit raised. A tax benefit (a deferred tax asset on a section 80JJAA deduction) was recorded. Consolidated FY26 profit moved from ₹140.9 crore to ₹143.2 crore, and earnings per share from ₹24.63 to ₹25.02. March-quarter profit moved from ₹38.1 crore to ₹40.4 crore. FY26 net worth is now ₹1,082 crore, against ₹1,091 crore before the revision - Supplier finance. Dues of ₹18.5 crore under supplier finance arrangements were moved out of "trade payables" into "other financial liabilities". In such an arrangement a bank pays the supplier early and the company repays the bank later, so it works like a short-term loan - Cash flow statement redone. The original had put some items in the wrong place: fair-value gains on investments, bank deposits made and withdrawn, and movements in stock, payables and other liabilities. Most of these were moves between lines. Cash from operations changed only from ₹116.5 crore to ₹115.2 crore, cash from investing from minus ₹107.1 crore to minus ₹105.8 crore, and the net change in cash did not change
The filing shows FY25 restated but gives no restated figures for FY24 or FY23. Because the net worth adjustment was already ₹105 crore on 1 April 2024, those years may also be affected. I do not know.
Why it matters: net worth at March 2025 was about 12% lower than first reported, a profit figure approved by the board and auditors was revised three months later, and the cash flow statement had errors. The company also put off its annual general meeting. Exchange filings show a 24 June letter postponing it, the notice approved only in late August, and a new date of 30 September. I did not find the reason. The numbers in the company's August presentation and in data sites such as the ₹141 crore profit figure come from before the revision. I use the revised numbers where I could.
Is profit turning into cash?
Only partly, and the company's own cash flow had errors.
- FY26 cash from operations was ₹115 crore (revised), 81% of profit and about 46% of operating profit - In FY25 it was only ₹64 crore against ₹127 crore of profit - Free cash flow (cash from operations minus capex) was minus ₹141 crore in FY24 and minus ₹108 crore in FY25 while Jammu was built. It was about plus ₹55 crore in FY26 on the data site's count (cash from operations of about ₹117 crore before the revision, less capex of about ₹62 crore)
₹ crore (consolidated, 31 March) FY25 FY26 --------- Fixed assets 830 842 Plant under construction 23 16 Total assets 1,568 1,836 Net worth (equity plus reserves) 959 (948 restated) 1,091 (1,082 revised) Borrowings (money owed to lenders) 338 344 Inventory 208 283 Trade receivables (money customers owe) 332 437 Trade payables (money owed to suppliers) 202 319 Cash and liquid funds 68 45
Balance sheet figures are from the data site and are before the August revision unless shown otherwise.
- Customers owe about 27% of a year's sales. Receivables of ₹437 crore are about 98 debtor days by the data site's count (about 97 in FY24 and FY25). I found no ageing table in the filings I read - Stock is rising. The average time stock sits before it is sold (inventory days) went from 91 days in FY24 to 125 days in FY26. Management says the working capital for Jammu was already built up in FY26 - Suppliers fund part of the business. Payable days rose from 113 in FY24 to 141 in FY26. That may include the supplier finance above - Working capital cycle. The data site shows 82 days. Management says the group runs at 90 days, give or take 10, at June 2026. The two use different bases - Fixed assets are 46% of total assets. This is not an asset-light business - Debt is moderate. Borrowings of ₹344 crore against revised net worth of ₹1,082 crore give debt-to-equity of about 0.32. Interest cover was about 12 times in FY26 on the data site's count. Management said interest on new projects is added to the plant's cost instead of being charged as an expense straight away. It reaches profit later, through depreciation, once the plant is ready
Returns on capital are modest. ROCE was 15.0% and return on equity 13.7% in FY26 on the data site's count, against 28% to 31% in FY21 and FY22. The company pays a small dividend (a payout of about 8% and a yield of about 0.2%).
Did management deliver what it promised?
Guidance (date given) Target What happened Verdict ------------ Early guidance, cited in November 2025 Jammu sales of about ₹400 crore in FY26 Cut to ₹270–280 crore in November 2025 after API price falls Missed, then reset November 2025 call Jammu sales ₹270–280 crore in FY26 About ₹300 crore Beat January 2026 call Jammu sales ₹280–290 crore in FY26 About ₹300 crore Met January and May 2026 calls Jammu to turn operating-profit positive in FY27 ₹1–1.5 crore positive in the June 2026 quarter Met, on time November 2025 and January 2026 calls Margin around 15% to 17% 15.4% in FY26; 16.0% in June 2026 quarter Met November 2025 call Revenue growth of 20%+ FY26 up 31%; June 2026 quarter up 34% Beat May 2026 call Profit to grow faster than sales in FY27 June 2026 quarter: profit up 42%, EBITDA up 33%, sales up 34% On track May 2026 call A Baddi block for ₹150–170 crore, with ₹450–500 crore of potential sales Not firmed up. On 22 August the board approved a smaller ₹45 crore addition of two tablet and capsule lines at Baddi Changed
The Jammu sales forecast was cut once, then beaten. The margin and growth targets set so far have been met, but the FY27 targets are still unproven after one quarter. The accounts revision raises questions about how reliable the reporting is. It does not by itself show that the underlying earnings are poor.
What management says it will do (its own targets)
These are management's forward-looking statements from the May and August 2026 calls. They are not promises.
FY27: - Volume growth of 20% or more. Management said guidance is always on volume, and declined to raise it after 34% growth in the June quarter - Profit to grow faster than sales - EBITDA margin of 15% to 16%, give or take 2 percentage points. A medium-term margin of 17% to 18%. The MD said 20% is "very high expectation" - Gross margin of 35.5%, give or take 2 points - Working capital cycle of 90 days, give or take 10 - Research and development spending of 0.7% to 1% of sales - Base businesses to grow in the early teens, and Jammu to add on top to reach 20%+. Sharon to grow in the early teens
Jammu: - Utilisation is 25% to 30% on an annual basis. Sales were ₹107 crore in the June quarter, against ₹90 crore in March - Capacity for penem, beta-lactam and cephalosporin products is enough for the next 2 to 3 years - Peak sales potential of ₹1,400 crore at 65% to 70% utilisation, including government incentives, over a 3 to 4 year ramp. The ₹1,000 crore mark needs approvals in countries outside the regulated markets. Management expects these by March 2027 - At best use, annual sales of more than 3 times the value of the plant's assets. Margin to match the base business once it matures
Capex: - Maintenance capex of ₹20 crore to ₹25 crore a year in FY27 and FY28. Growth and debottlenecking capex of ₹20 crore to ₹30 crore a year - Baddi addition approved on 22 August: two tablet and capsule lines, about ₹45 crore, 18 to 22 months, paid from bank loans and company cash. The existing block runs at 85% to 90% - A larger Baddi block on a new plot bought last year is still being planned. In May management said ₹150–170 crore of capex across FY27 and FY28 and ₹450–500 crore of potential sales - Future expansions in steps of ₹200–250 crore each, smaller than Jammu, to limit the margin drag - New dosage forms and drug categories not offered today, and peptides, are under study
Other: - Semaglutide (a diabetes and weight-loss drug): trial batches are being made, with no launch date. Management says it will go in the second wave, not the first - The company expects to keep a cost-plus model. Raw material price changes are passed on to customers - New R&D centre in Panchkula, Haryana (shown as upcoming in the presentation) - The Q2 call in November 2025 mentioned no fund-raise, and none is mentioned since
Market size and the demand story
According to market research firm IMARC, India's CDMO market was about USD 8.5 billion in 2025 and is forecast to reach about USD 16.5 billion by 2034, which is growth of 7.4% a year. Other research firms publish much higher growth rates, up to 14% a year, so the forecasts disagree. At about ₹88 to the dollar, Innova's CDMO sales of ₹1,133 crore are about 1.5% of the 2025 market (my estimate).
- Tailwinds: drug companies outsource more manufacturing. India's revised Schedule M quality rules now apply across the country. Management says plants that comply, such as Innova's, gain from this. Management said raw material prices have risen but supply has not been short - Headwinds: Baddi's core categories are near capacity. Prices of cephalosporin ingredients fell in the middle of FY26, which cut Jammu's sales. Many CDMOs compete for the same customers
Who owns it
Holder Dec 2023 Dec 2024 Jun 2025 Dec 2025 Jun 2026 ------------------ Promoters 50.90% 50.90% 50.90% 50.90% 50.90% Foreign funds (FIIs) 3.57% 0.74% 0.23% 0.10% 0.34% Domestic funds (DIIs) 10.31% 19.96% 19.67% 20.24% 19.92% Public 35.22% 28.41% 29.20% 28.76% 28.84%
Promoters have not sold any shares since the listing, and the data site shows no pledge. Domestic funds (mutual funds and insurers) hold about 20%. Foreign funds have all but left. The number of shareholders fell from 1,39,117 to 35,881.
Mutual funds: estimates based on monthly portfolio disclosures show Bandhan Small Cap Fund adding about 2.62 lakh shares in June 2026 at an estimated price near ₹978, and a Trust Mutual Fund multi-cap scheme adding smaller amounts in June and July at estimated prices near ₹974 to ₹978. These are estimates, not exchange trades. I did not find any famous individual investor in the exchange bulk-deal data after the listing week.
Fundraising: I found no QIP, preferential issue, warrants or rights issue since the listing in the filings I checked.
Valuation: pricing in the Jammu ramp-up
Company P/E ROCE Market cap (₹ crore) ------------ Concord Biotech 51.3 17.1% 14,242 Syngene 47.4 10.0% 14,023 Innova Captab 41.2 15.0% 6,352 Akums Drugs 38.8 14.9% 11,834 Windlas Biotech 29.5 15.9% 1,959
Akums Drugs and Windlas Biotech are the closest: Indian contract makers of medicines for other brands. Syngene and Concord Biotech are research and ingredient businesses, so they are rougher comparisons. Innova's return on capital is similar to Akums and Windlas. It trades slightly above Akums and well above Windlas.
For the whole business: market cap ₹6,352 crore, plus borrowings of ₹344 crore, minus cash and liquid funds of ₹45 crore, is about ₹6,650 crore. That is about 25 times last-twelve-month EBITDA of about ₹268 crore (FY26's ₹250 crore plus the June 2026 quarter's ₹75 crore, minus the June 2025 quarter's ₹57 crore; my calculation).
What the price needs. These are illustrations, not forecasts. Shares in issue are 5.72 crore.
If profit is Then P/E at ₹1,110 is How it could arise --------- ₹157 crore about 40x The last twelve months, after the August revision ₹176 crore about 36x FY27 sales up 20% to ₹1,956 crore at a 9.0% profit margin (FY26 was 8.8% and the June quarter 9.4%) ₹176 crore about 36x The June quarter's ₹44 crore repeated four times ₹221 crore about 29x FY28 sales up another 20% at a 9.4% margin
At today's price you are paying about 40 times the profit the company already earns. To bring that to about 29, you need two more years of 20% sales growth with margins held. That is exactly what management guides for, and the Jammu plant is the part of it that is not yet proven.
Risks
- The accounts were revised. A deferred tax liability was missing for about three years, net worth was overstated by about ₹115 crore, the cash flow statement had errors, and the AGM was delayed. The auditor gave an unmodified opinion on the revised accounts, but investors should ask whether other numbers could move - Jammu may ramp slowly. The plant is 25% to 30% used. The ₹1,000 crore sales milestone depends on approvals in other countries by March 2027. Its first sales forecast of ₹400 crore for FY26 had to be cut - Heavy working capital. Customers owe about 27% of annual sales, stock days are rising, and free cash flow was negative for two years. The cash cycle is about 82 to 90 days - Customer concentration is unknown. The filings I read name no customer - Cost-plus pricing. API (active ingredient) prices are passed on to customers, but timing gaps can lift or cut margins from quarter to quarter - More capex is coming. The Baddi addition and a possible ₹150–170 crore block, plus later steps of ₹200–250 crore, will each weigh on margin until they fill up - Foreign funds have left. Their holding fell from 3.6% to 0.3%. Domestic funds hold about 20%, so a change in their view would matter - Valuation. About 40 times profit for a business with ROCE of 15%
The takeaway Innova Captab is growing at 30%+ with a stable 15% to 16% margin, and its new Jammu plant has just turned profitable. But the company revised several accounting items in August, including a ₹115 crore overstatement of net worth at March 2025, and the stock is priced at about 40 times profit. Wait for the September-quarter results, due by 14 November, to check that profit growth continues and that no further revisions appear.
Note: I am not a SEBI-registered investment advisor. This article is for educational purposes only and is not investment advice. Please consult a registered financial advisor before making investment decisions.
Sources
- https://nsearchives.nseindia.com/corporate/INNOVACAPTAB14082026183853IntimationofTranscriptofEarningCallSigned.pdf - https://nsearchives.nseindia.com/corporate/INNOVACAPTAB14052026171021ICLReg30IntimationofTranscript.pdf - https://nsearchives.nseindia.com/corporate/INNOVACAPTAB11082026203844InvestorPresentationReg30.pdf - https://www.bseindia.com/xml-data/corpfiling/AttachHis/49974545-6b0b-4f9f-935c-7e69cbd1d5cc.pdf - https://www.arthneeti.com/stocks/innova-captab-ltd/concall/q2-fy26-earnings-call-analysis - https://www.arthneeti.com/stocks/innova-captab-ltd/concall/q3-fy26-earnings-call-analysis - https://www.imarcgroup.com/india-cdmo-market - https://query1.finance.yahoo.com/v8/finance/chart/INNOVACAP.NS